Welcome to our dedicated page for CATALYST PHARMACEUTICALS SEC filings (Ticker: CPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Catalyst Pharmaceuticals files regulatory disclosures that document material events for its rare-disease biopharmaceutical business and Nasdaq-listed common stock. Recent Form 8-K and 8-K/A filings cover operating results and business updates, Regulation FD presentation materials, press-release exhibits, and capital-structure matters including a board-authorized share repurchase program.
The filings also record company-specific legal and intellectual property disclosures, including FIRDAPSE Orange Book patent litigation, amendments to prior material-event reports, and settlement-related corrections. These documents tie formal disclosures to Catalyst’s commercial products, governance actions, exhibit filings, and public-company reporting obligations.
Catalyst Pharmaceuticals Chief Strategy Officer Preethi Sundaram reported dispositions tied to the company’s acquisition by Angelini Pharma S.p.A. On July 15, 2026 she disposed of 54,804 shares of common stock at $31.50 per share, and all reported RSUs and stock options were canceled and converted into cash rights, leaving her with no reported common or derivative holdings.
Catalyst Pharmaceuticals President and CEO Richard J. Daly reported the disposition of 271,266 shares of common stock at $31.50 per share on July 15, 2026, in connection with the acquisition of Catalyst by Angelini Pharma S.p.A.
All reported restricted stock units and stock options were cancelled and converted into cash rights based on the $31.50 merger price, with option payouts equal to the merger price minus the exercise price per share. After these transactions, no holdings of the reported awards remain.
CATALYST PHARMACEUTICALS, INC. reports that Chief Medical Officer William T. Andrews disposed of 2,309 common shares at $31.50 per share in a transaction with the issuer, in connection with the acquisition by Angelini Pharma S.p.A. (the Merger).
On the same date, all of his reported RSUs (29,776 and 12,209 units) and stock options (98,652 at a $22.77 exercise price and 124,447 at $24.90) vested, were cancelled, and converted into cash rights based on the $31.50 merger price, leaving no reported remaining holdings in these awards.
CATALYST PHARMACEUTICALS director Molly Harper reported the disposition to the issuer of 3,694 common shares at $31.50 per share on July 15, 2026, in connection with the acquisition of the company by Angelini Pharma S.p.A. In the same merger-related event, she also disposed of multiple restricted stock units and stock options, which were cancelled and converted into cash rights calculated using the $31.50 merger price, leaving the reported positions at zero.
Catalyst Pharmaceuticals chief financial officer Michael Wayne Kalb reported dispositions of common stock, restricted stock units and stock options on July 15, 2026, in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. The reported awards vested in full, were cancelled, and converted into rights to receive cash based on a price of $31.50 per share or, for options, the excess of $31.50 over each option’s exercise price, leaving the reported positions at zero.